Clearway Health, a Boston-based company that partners with hospitals and health systems to plan, build and operate specialty pharmacy programs, announced on Tuesday its 2026 Certification by Great Place To Work for the fourth consecutive year.
The award is based entirely on what current team members say about their experience working at Clearway Health. This year, Clearway Health team members indicated:
84% - Clearway Health is a Great Place to work compared to 57 % of team members at a typical US-based company.
92% - They feel a sense of pride when they look at what the company accomplished.
94% - They feel good about the ways they contribute to the community.
92% - They believe that clients would rate the service Clearway Health delivers as excellent.
According to Great Place To Work research, job seekers are 4.5 times more likely to find a great boss at a Certified great workplace. Additionally, team members at Certified workplaces are 93% more likely to look forward to coming to work, and are twice as likely to be paid fairly and have a fair chance of promotion.
Great Place To Work says that it is the global authority on workplace culture, employee experience and the leadership behaviours proven to deliver market-leading revenue, retention and increased innovation.
Ranok Therapeutics reports positive Phase 1a clinical results for KRAS G12D inhibitor RNK08954
Avid Bioservices names new chief commercial officer
AnaCardio reports Phase 1b/2a data showing cardiac function gains with AC01
Inhibrx reports positive interim Phase 2 data for INBRX-106 in first-line head and neck cancer
Anixa Biosciences reports extended survival signals in Phase 1 ovarian cancer CAR-T trial
Oncopeptides plans EMA filing to broaden Pepaxti indication
GSK partners with SBP Group to accelerate China launch of bepirovirsen
Harbour BioMed's HBM7004 receives US FDA IND clearance for Phase I trial
PureHealth Research introduces Berberine-infused natural GLP-1 supplements
Innovent's IBI363 receives third Chinese regulatory BTD for MSS/pMMR CRC
MHRA approves Efmody for adrenal insufficiency treatment
European Commission approves Bristol Myers Squibb's Sotyktu for psoriatic arthritis
Rznomics receives FDA RMAT designation for HCC candidate RZ‑001